⌕
Pacira BioSciences · PCRX · Nasdaq
Tenet 56 · Mixed
Compare
$36.48+0.05%At closeTenet 56 · Mixed
$36.48+0.02 (+0.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pacira BioSciences (PCRX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 46% below its peak, net margin 1.0%, and free cash flow (~$136.7M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (110%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3.6%
726.4
FY21→FY25CAGR +7.6%/yr
Net income ($M)—
7.0
one-off year: see footnoteCAGR −36.0%/yr
Free cash flow ($M)▼23.5%
136.7
FY21→FY25CAGR +14.4%/yr
Diluted EPS—
0.16
FY21→FY25CAGR −35.4%/yr
What the receipts whisper · what a headline number hides
Share count
−1.3%

45.6mn → 45.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$15.3M

+44.2% YoY in FY25 · 2.1% of revenue.

Returns vs FCF
110%

$150.5M returned vs $136.7M of FCF in FY25. The gap comes off the balance sheet (see net cash).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)726.4Revenue−149.7COGS576.7Gross profit−117.3R&D−368.8SG&A19.2Op income−12.2Tax & other7.0Net income

1¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 74.1% → 79.4%. Net margin 1.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
743,301.0726,411.0700,966.0674,978.01,333,646.0541,533.0▲3.6%+7.6%
Cost of revenue
158,109.0149,749.0170,428.0184,669.0199,295.0140,255.0▼12.1%+1.7%
Gross profit
585,192.0576,662.0530,538.0490,309.01,134,351.0401,278.0▲8.7%+9.5%
Research & development
122,801.0117,312.081,577.076,257.084,797.055,545.0▲43.8%+20.6%
Selling, general & admin
371,201.0368,759.0294,099.0269,441.0254,516.0199,345.0▲25.4%+16.6%
Total operating expenses
549,411.0557,471.0603,909.0402,634.01,060,688.0311,354.0▼7.7%+15.7%
Operating incomefeeds ROC rank
35,781.019,191.0−73,371.087,675.060,024.089,924.0—−32.0%
Other income, net
1,157.0−2,317.010,265.0−25,974.0−33,420.0−33,520.0——
Pretax income
36,938.016,874.0−63,106.061,701.026,604.056,404.0—−26.0%
Income tax
−789.09,840.036,454.019,746.0−5,214.014,424.0▼73.0%−9.1%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
37,727.07,034.0−99,560.041,955.031,818.041,980.0—−36.0%
Per share
Diluted EPSbuyback-sensitive
0.940.16−2.150.890.340.92—−35.4%
Diluted shares (mn)
40.8345.0446.2451.9846.5445.63▼2.6%−0.3%
Margins
Gross margin73rd pct in Healthcare
78.7%79.4%75.7%72.6%85.1%74.1%▲3.7pp+5.3pp
Operating margin
4.8%2.6%−10.5%13.0%4.5%16.6%▲13.1pp−14.0pp
Net margin55th pct in Healthcare
5.1%1.0%−14.2%6.2%2.4%7.8%▲15.2pp−6.8pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −20% vs a 26% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was −58% vs a 26% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Pacira BioSciences' revenue last fiscal year?

Pacira BioSciences reported revenue of $726.4M in fiscal 2025, up 3.6% from fiscal 2024.

What was Pacira BioSciences' net income?

Pacira BioSciences reported net income of $7.0M in fiscal 2025, a net margin of 1.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.